

# Jarushka Naidoo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4057376/publications.pdf>

Version: 2024-02-01

108  
papers

13,870  
citations

53794

45  
h-index

45317

90  
g-index

111  
all docs

111  
docs citations

111  
times ranked

17958  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1691-1695.  | 2.2  | 11        |
| 2  | Immune-related adverse events and the balancing act of immunotherapy. <i>Nature Communications</i> , 2022, 13, 392.   | 12.8 | 125       |
| 3  | Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.  | 1.6  | 445       |
| 4  | Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. <i>Cancer Treatment Reviews</i> , 2022, 104, 102350.  | 7.7  | 18        |
| 5  | Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. <i>Lung Cancer</i> , 2022, 166, 84-93.   | 2.0  | 7         |
| 6  | Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2405-2420. | 4.2  | 10        |
| 7  | Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis: Focus on proactive monitoring, diagnosis, and management. <i>Cancer Treatment Reviews</i> , 2022, 106, 102378.           | 7.7  | 60        |
| 8  | Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2896-2908.e4.  | 0.7  | 9         |
| 9  | Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. , 2022, 10, e004670.   |      | 21        |
| 10 | An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis. <i>Current Oncology</i> , 2022, 29, 4342-4353.  | 2.2  | 0         |
| 11 | Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8541-8541.                     | 1.6  | 11        |
| 12 | Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. , 2021, 9, e001731.  |      | 45        |
| 13 | A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2021, 27, 2571-2583.  | 7.0  | 22        |
| 14 | Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC: an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 860-867.   | 1.1  | 323       |
| 15 | Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1030-1041.  | 1.1  | 79        |
| 16 | Immune-Related Adverse Events and Efficacy: "The More It Hurts, the Better It Works?" Reply. <i>JAMA Oncology</i> , 2021, 7, 945.   | 7.1  | 0         |
| 17 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.   |      | 298       |
| 18 | Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.   |      | 87        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. <i>Nature</i> , 2021, 596, 126-132.  | 27.8 | 234       |
| 20 | Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473.  |      | 33        |
| 21 | Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies. <i>Oncologist</i> , 2021, 26, e1822-e1832.   | 3.7  | 31        |
| 22 | Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis. <i>Cancer Investigation</i> , 2021, 39, 789-796. | 1.3  | 5         |
| 23 | Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100220.   | 1.1  | 4         |
| 24 | Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 3978-3992.     | 1.6  | 121       |
| 25 | Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 123-131.   | 2.7  | 4         |
| 26 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 4073-4126.   | 1.6  | 580       |
| 27 | Lung cancer and family-centered concerns. <i>Supportive Care in Cancer</i> , 2020, 28, 497-505.   | 2.2  | 2         |
| 28 | Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 99-111.  | 13.2 | 141       |
| 29 | Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e169-e170.  | 2.6  | 24        |
| 30 | Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.   | 1.6  | 135       |
| 31 | A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities. <i>Oncologist</i> , 2020, 25, e1589-e1592.                               | 3.7  | 3         |
| 32 | Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <i>Lancet Oncology</i> , The, 2020, 21, e398-e404.                                     | 10.7 | 74        |
| 33 | Multidisciplinary Approach to Immune-Mediated Diarrhea and Colitis From Immunotherapy for Cancer. <i>JCO Oncology Practice</i> , 2020, 16, 462-463.   | 2.9  | 2         |
| 34 | Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1952.                   | 7.1  | 241       |
| 35 | Radiation pneumonitis after definitive chemoradiation and durvalumab for non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 150, 249-251.   | 2.0  | 7         |
| 36 | Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. , 2020, 8, e001282.   |      | 108       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | 4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 73-73. | 0.6  | 0         |
| 38 | Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. <i>Current Oncology Reports</i> , 2020, 22, 56.  | 4.0  | 23        |
| 39 | Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918.  | 13.7 | 1,395     |
| 40 | Principles of Immunotherapy in Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 187-198.  | 1.0  | 19        |
| 41 | Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. , 2020, 8, e000984.  |      | 15        |
| 42 | Chronic immune checkpoint inhibitor pneumonitis. , 2020, 8, e000840.   |      | 55        |
| 43 | Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e435-e444.  | 2.6  | 46        |
| 44 | Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 332-338.  | 0.9  | 140       |
| 45 | Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1327-1337.                              | 7.0  | 90        |
| 46 | Information Visualization Platform for Postmarket Surveillance Decision Support. <i>Drug Safety</i> , 2020, 43, 905-915.   | 3.2  | 6         |
| 47 | Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100074.                                 | 1.1  | 10        |
| 48 | Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. , 2020, 8, e001675.  |      | 9         |
| 49 | NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 230-241.  | 4.9  | 284       |
| 50 | 681â€“...Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors. , 2020, , .  |      | 0         |
| 51 | Immune-Related Adverse Events: A Case-Based Approach. <i>Frontiers in Oncology</i> , 2019, 9, 530.   | 2.8  | 31        |
| 52 | Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. <i>Journal of Oncology Practice</i> , 2019, 15, e825-e834.   | 2.5  | 37        |
| 53 | Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitorâ€“related Pneumonitis. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, e31-e43.     | 5.6  | 97        |
| 54 | Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019, 115, 854-868.   | 3.8  | 311       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Genome-wide cell-free DNA fragmentation in patients with cancer. <i>Nature</i> , 2019, 570, 385-389.   | 27.8 | 764       |
| 56 | Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. <i>Journal of Clinical Oncology</i> , 2019, 37, 2738-2745.  | 1.6  | 138       |
| 57 | Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e470-e479.  | 2.6  | 80        |
| 58 | Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. , 2019, 7, 40.   |      | 42        |
| 59 | Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, 494-502.   | 1.1  | 114       |
| 60 | Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1204-1213.   | 0.9  | 75        |
| 61 | Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1214-1225.  | 0.9  | 226       |
| 62 | The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. <i>Journal of Clinical Investigation</i> , 2019, 129, 4305-4315.   | 8.2  | 100       |
| 63 | A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 712-720.   | 4.9  | 71        |
| 64 | Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 255-289.   | 4.9  | 393       |
| 65 | Successful Treatment of Scar Pain with Scrambler Therapy. <i>Cureus</i> , 2019, 11, e5903.   | 0.5  | 4         |
| 66 | Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1976-1986.  | 27.0 | 1,495     |
| 67 | Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 916-925. | 0.8  | 257       |
| 68 | Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 553-557.   | 3.4  | 119       |
| 69 | PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S4034-S4037.   | 1.4  | 5         |
| 70 | 2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 44-45.   | 0.6  | 0         |
| 71 | Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer. <i>Chest</i> , 2018, 154, 1416-1423.   | 0.8  | 230       |
| 72 | Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1930-1939.   | 1.1  | 282       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. , 2018, 6, 104.  |     | 55        |
| 74 | Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 467-472.  | 4.9 | 13        |
| 75 | Preoperative contralateral lung radiation dose is associated with postoperative pulmonary toxicity in patients with locally advanced non-small cell lung cancer treated with trimodality therapy. Practical Radiation Oncology, 2018, 8, e239-e248. | 2.1 | 0         |
| 76 | Frequency, impact and a preclinical study of novel <i>ERBB</i> gene family mutations in HER2-positive breast cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877829.   | 3.2 | 11        |
| 77 | Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer. Current Treatment Options in Oncology, 2018, 19, 46.   | 3.0 | 16        |
| 78 | The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. Cancer Immunology Research, 2018, 6, 888-899.   | 3.4 | 118       |
| 79 | An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition. Journal of Clinical Investigation, 2018, 129, 75-77.   | 8.2 | 1         |
| 80 | A multidisciplinary toxicity team for cancer immunotherapy-related adverse events.. Journal of Clinical Oncology, 2018, 36, 6538-6538.  | 1.6 | 9         |
| 81 | Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. Oncologist, 2017, 22, 627-630.  | 3.7 | 74        |
| 82 | Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. Immunotherapy, 2017, 9, 5-8.   | 2.0 | 20        |
| 83 | Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discovery, 2017, 7, 264-276.  | 9.4 | 706       |
| 84 | Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Annals of the Rheumatic Diseases, 2017, 76, 43-50.   | 0.9 | 317       |
| 85 | Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of Clinical Oncology, 2017, 35, 709-717.  | 1.6 | 829       |
| 86 | Reply to M. Nishino et al. Journal of Clinical Oncology, 2017, 35, 1629-1630.   | 1.6 | 1         |
| 87 | Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. PLoS ONE, 2017, 12, e0182665.  | 2.5 | 54        |
| 88 | The next frontier in non-small cell lung cancer: synergizing radiation therapy and immune checkpoint blockade. Clinical Advances in Hematology and Oncology, 2017, 15, 615-625.   | 0.3 | 6         |
| 89 | Pneumonitis From Anti-PD-1/ PD-L1 Therapy. Oncology, 2017, 31, 739-46, 754.   | 0.5 | 23        |
| 90 | Immune-Related Adverse Events From Immune Checkpoint Inhibitors. Clinical Pharmacology and Therapeutics, 2016, 100, 242-251.  | 4.7 | 84        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016, 4, 383-389.   | 3.4 | 247       |
| 92  | Immunotherapy for Lung Cancer: No Longer an Abstract Concept. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 771-782.  | 2.1 | 12        |
| 93  | The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. <i>Lung Cancer</i> , 2016, 102, 21-27. | 2.0 | 11        |
| 94  | Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. <i>Clinical Lung Cancer</i> , 2016, 17, e121-e129.   | 2.6 | 116       |
| 95  | Adaptive Neoadjuvant Chemotherapy Guided by 18 F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial. <i>Journal of Thoracic Oncology</i> , 2016, 11, 537-544.                                 | 1.1 | 42        |
| 96  | Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. <i>Clinical Cancer Research</i> , 2016, 22, 3618-3629. | 7.0 | 342       |
| 97  | KRAS-Mutant Lung Cancers in the Era of Targeted Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, 893, 155-178.   | 1.6 | 23        |
| 98  | Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. <i>PLoS ONE</i> , 2016, 11, e0146063.                                | 2.5 | 17        |
| 99  | What does the future hold for immunotherapy in cancer?. <i>Annals of Translational Medicine</i> , 2016, 4, 177-177.   | 1.7 | 9         |
| 100 | The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?. <i>Npj Breast Cancer</i> , 2015, 1, .  | 5.2 | 0         |
| 101 | Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. <i>Cancer</i> , 2015, 121, 3212-3220.  | 4.1 | 160       |
| 102 | Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas. <i>Cancer</i> , 2015, 121, 2078-2082.  | 4.1 | 15        |
| 103 | Emerging immunotherapy strategies in breast cancer. <i>Immunotherapy</i> , 2014, 6, 195-209.  | 2.0 | 23        |
| 104 | Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab. <i>Cancer Immunology Research</i> , 2014, 2, 127-132.                  | 3.4 | 122       |
| 105 | Immune Checkpoint Blockade. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 585-600.  | 2.2 | 70        |
| 106 | Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation?. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1215-1221.   | 1.1 | 35        |
| 107 | An Irish breast cancer survivorship study: Are we meeting our patients' needs?. <i>Journal of Clinical Oncology</i> , 2013, 31, e20687-e20687.  | 1.6 | 0         |
| 108 | Should patients with extrapulmonary small cell carcinoma receive prophylactic cranial irradiation? An Irish experience.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2609-2609.                             | 1.6 | 3         |